Search

Your search keyword '"Watkins, David I."' showing total 733 results
Start Over Author "Watkins, David I."
733 results on '"Watkins, David I."'

3. Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies

Author

Haslwanter, Denise, Lasso, Gorka, Wec, Anna Z., Furtado, Nathália Dias, Raphael, Lidiane Menezes Souza, Tse, Alexandra L., Sun, Yan, Stransky, Stephanie, Pedreño-Lopez, Núria, Correia, Carolina Argondizo, Bornholdt, Zachary A., Sakharkar, Mrunal, Avelino-Silva, Vivian I., Moyer, Crystal L., Watkins, David I., Kallas, Esper G., Sidoli, Simone, Walker, Laura M., Bonaldo, Myrna C., and Chandran, Kartik

Published
2022
Full Text
View/download PDF

4. Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus

Author

Zhao, Fangzhu, Berndsen, Zachary T., Pedreño-Lopez, Nuria, Burns, Alison, Allen, Joel D., Barman, Shawn, Lee, Wen-Hsin, Chakraborty, Srirupa, Gnanakaran, Sandrasegaram, Sewall, Leigh M., Ozorowski, Gabriel, Limbo, Oliver, Song, Ge, Yong, Peter, Callaghan, Sean, Coppola, Jessica, Weisgrau, Kim L., Lifson, Jeffrey D., Nedellec, Rebecca, Voigt, Thomas B., Laurino, Fernanda, Louw, Johan, Rosen, Brandon C., Ricciardi, Michael, Crispin, Max, Desrosiers, Ronald C., Rakasz, Eva G., Watkins, David I., Andrabi, Raiees, Ward, Andrew B., Burton, Dennis R., and Sok, Devin

Published
2022
Full Text
View/download PDF

5. Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine

Author

Wec, Anna Z., Haslwanter, Denise, Abdiche, Yasmina N., Shehata, Laila, Pedreño-Lopez, Nuria, Moyer, Crystal L., Bornholdt, Zachary A., Lilov, Asparouh, Nett, Juergen H., Jangra, Rohit K., Brown, Michael, Watkins, David I., Ahlm, Clas, Forsell, Mattias N., Rey, Félix A., Barba-Spaeth, Giovanna, Chandran, Kartik, and Walker, Laura M.

Published
2020

6. Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans

Author

Grifoni, Alba, Pham, John, Sidney, John, O'Rourke, Patrick H, Paul, Sinu, Peters, Bjoern, Martini, Sheridan R, de Silva, Aruna D, Ricciardi, Michael J, Magnani, Diogo M, Silveira, Cassia GT, Maestri, Alvino, Costa, Priscilla R, de-Oliveira-Pinto, Luzia Maria, de Azeredo, Elzinandes Leal, Damasco, Paulo Vieira, Phillips, Elizabeth, Mallal, Simon, de Silva, Aravinda M, Collins, Matthew, Durbin, Anna, Diehl, Sean A, Cerpas, Cristhiam, Balmaseda, Angel, Kuan, Guillermina, Coloma, Josefina, Harris, Eva, Crowe, James E, Stone, Mars, Norris, Phillip J, Busch, Michael, Vivanco-Cid, Hector, Cox, Josephine, Graham, Barney S, Ledgerwood, Julie E, Turtle, Lance, Solomon, Tom, Kallas, Esper G, Watkins, David I, Weiskopf, Daniela, and Sette, Alessandro

Subjects
Vaccine Related, Infectious Diseases, Immunization, Emerging Infectious Diseases, Biodefense, Prevention, Vector-Borne Diseases, Biotechnology, 2.1 Biological and endogenous factors, Aetiology, Infection, Inflammatory and immune system, Good Health and Well Being, Adolescent, Adult, Aged, Child, Child, Preschool, Cohort Studies, Cross Reactions, Dengue Vaccines, Dengue Virus, Epitopes, T-Lymphocyte, Female, Humans, Male, Middle Aged, T-Lymphocytes, Vaccines, Attenuated, Young Adult, Zika Virus, Zika Virus Infection, ZIKV, DENV, T cells, heterologous immunity, cross-reactivity, immunodominance, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology
Abstract

While progress has been made in characterizing humoral immunity to Zika virus (ZIKV) in humans, little is known regarding the corresponding T cell responses to ZIKV. Here, we investigate the kinetics and viral epitopes targeted by T cells responding to ZIKV and address the critical question of whether preexisting dengue virus (DENV) T cell immunity modulates these responses. We find that memory T cell responses elicited by prior infection with DENV or vaccination with tetravalent dengue attenuated vaccines (TDLAV) recognize ZIKV-derived peptides. This cross-reactivity is explained by the sequence similarity of the two viruses, as the ZIKV peptides recognized by DENV-elicited memory T cells are identical or highly conserved in DENV and ZIKV. DENV exposure prior to ZIKV infection also influences the timing and magnitude of the T cell response. ZIKV-reactive T cells in the acute phase of infection are detected earlier and in greater magnitude in DENV-immune patients. Conversely, the frequency of ZIKV-reactive T cells continues to rise in the convalescent phase in DENV-naive donors but declines in DENV-preexposed donors, compatible with more efficient control of ZIKV replication and/or clearance of ZIKV antigen. The quality of responses is also influenced by previous DENV exposure, and ZIKV-specific CD8 T cells from DENV-preexposed donors selectively upregulated granzyme B and PD1, unlike DENV-naive donors. Finally, we discovered that ZIKV structural proteins (E, prM, and C) are major targets of both the CD4 and CD8 T cell responses, whereas DENV T cell epitopes are found primarily in nonstructural proteins.IMPORTANCE The issue of potential ZIKV and DENV cross-reactivity and how preexisting DENV T cell immunity modulates Zika T cell responses is of great relevance, as the two viruses often cocirculate and Zika virus has been spreading in geographical regions where DENV is endemic or hyperendemic. Our data show that memory T cell responses elicited by prior infection with DENV recognize ZIKV-derived peptides and that DENV exposure prior to ZIKV infection influences the timing, magnitude, and quality of the T cell response. Additionally, we show that ZIKV-specific responses target different proteins than DENV-specific responses, pointing toward important implications for vaccine design against this global threat.

Published
2017

8. Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies

Author

Pedreño-Lopez, Nuria, Dang, Christine M., Rosen, Brandon C., Ricciardi, Michael J., Bailey, Varian K., Gutman, Martin J., Gonzalez-Nieto, Lucas, Pauthner, Matthias G., Le, Khoa, Song, Ge, Andrabi, Raiees, Weisgrau, Kim L., Pomplun, Nicholas, Martinez-Navio, José M., Fuchs, Sebastian P., Wrammert, Jens, Rakasz, Eva G., Lifson, Jeffrey D., Martins, Mauricio A., Burton, Dennis R., Watkins, David I., and Magnani, Diogo M.

Published
2020
Full Text
View/download PDF

9. Travel Surveillance and Genomics Uncover a Hidden Zika Outbreak during the Waning Epidemic

Author

Grubaugh, Nathan D., Saraf, Sharada, Gangavarapu, Karthik, Watts, Alexander, Tan, Amanda L., Oidtman, Rachel J., Ladner, Jason T., Oliveira, Glenn, Matteson, Nathaniel L., Kraemer, Moritz U.G., Vogels, Chantal B.F., Hentoff, Aaron, Bhatia, Deepit, Stanek, Danielle, Scott, Blake, Landis, Vanessa, Stryker, Ian, Cone, Marshall R., Kopp, Edgar W., IV, Cannons, Andrew C., Heberlein-Larson, Lea, White, Stephen, Gillis, Leah D., Ricciardi, Michael J., Kwal, Jaclyn, Lichtenberger, Paola K., Magnani, Diogo M., Watkins, David I., Palacios, Gustavo, Hamer, Davidson H., Gardner, Lauren M., Perkins, T. Alex, Baele, Guy, Khan, Kamran, Morrison, Andrea, Isern, Sharon, Michael, Scott F., and Andersen, Kristian G.

Published
2019
Full Text
View/download PDF

10. Vaccine protection against SIVmac239 acquisition

Author

Martins, Mauricio A., Bischof, Georg F., Shin, Young C., Lauer, William A., Gonzalez-Nieto, Lucas, Watkins, David I., Rakasz, Eva G., Lifson, Jeffrey D., and Desrosiers, Ronald C.

Published
2019

11. A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced Fc?RIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques

Author

Moldt, Brian, Shibata-Koyama, Mami, Rakasz, Eva G., Schultz, Niccole, Kanda, Yutaka, Dunlop, D. Cameron, Finstad, Samantha L., Jin, Chenggang, Landucci, Gary, Alpert, Michael D., Dugast, Anne-Sophie, Parren, Paul I., Nimmerjahn, Falk, Evans, David T., Alter, Galit, Forthal, Donald N., Schmitz, Jorn E., Iida, Shigeru, Poignard, Pascal, Watkins, David I., Hessell, Ann J., and Burton, Dennis R.

Abstract

Eliciting neutralizing antibodies is thought to be a key activity of a vaccine against human immunodeficiency virus (HIV). However, a number of studies have suggested that in addition to neutralization, interaction of IgG with Fc gamma receptors (FcγR) may play an important role in antibody-mediated protection. We have previously obtained evidence that the protective activity of the broadly neutralizing human IgG1 anti-HIV monoclonal antibody (MAb) b12 in macaques is diminished in the absence of FcγR binding capacity. To investigate antibody-dependent cellular cytotoxicity (ADCC) as a contributor to FcγR-associated protection, we developed a nonfucosylated variant of b12 (NFb12). We showed that, compared to fully fucosylated (referred to as wild-type in the text) b12, NFb12 had higher affinity for human and rhesus macaque FcγRIIIa and was more efficient in inhibiting viral replication and more effective in killing HIV-infected cells in an ADCC assay. Despite these more potent in vitro antiviral activities, NFb12 did not enhance protection in vivo against repeated low-dose vaginal challenge in the simian-human immunodeficiency virus (SHIV)/macaque model compared to wild-type b12. No difference in protection, viral load, or infection susceptibility was observed between animals given NFb12 and those given fully fucosylated b12, indicating that FcγR-mediated activities distinct from FcγRIIIa-mediated ADCC may be important in the observed protection against SHIV challenge.

Published
2012

13. Support for the RV144 HIV Vaccine Trial

Author

Belshe, Robert, Franchini, Genoveffa, Girard, Marc P., Gotch, Frances, Kaleebu, Pontiano, Marthas, Marta L., McChesney, Michael B., McCullough, Rose, Mhalu, Fred, Salmon-Ceron, Dominique, Sekaly, Rafick-Pierre, Van Rompay, Koen, Verrier, Bernard, Wahren, Britta, Weissenbacher, Mercedes, Burton, Dennis R., Desrosiers, Ronald C., Doms, Robert W., Feinberg, Mark B., Hahn, Beatrice H., Hoxie, James A., Hunter, Eric, Landay, Alan L., Lederman, Michael M., Lieberman, Judy, McCune, Joseph M., Moore, John P., Nathanson, Neal, Picker, Louis, Richman, Douglas D., Rinaldo, Charles R., Stevenson, Mario, Watkins, David I., Wolinsky, Steven M., Zack, Jerome A., and Gallo, Robert C.

Published
2004

14. Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers

Author

Hessell, Ann J., Rakasz, Eva G., Poignard, Pascal, Hangartner, Lars, Landucci, Gary, Forthal, Donald N., Koff, Wayne C., Watkins, David I., and Burton, Dennis R.

Subjects
immunodeficiency-virus type-1, human monoclonal-antibody, hiv-1/siv chimeric virus, pbl-scid mice, simian immunodeficiency, dc-sign, dendritic cell, passive-immunization, vaginal transmission, macaque monkeys
Abstract

Developing an immunogen that elicits broadly neutralizing antibodies (bNAbs) is an elusive but important goal of HIV vaccine research, especially after the recent failure of the leading T cell based HIV vaccine in human efficacy trials. Even if such an immunogen can be developed, most animal model studies indicate that high serum neutralizing concentrations of bNAbs are required to provide significant benefit in typical protection experiments. One possible exception is provided by the anti-glycan bNAb 2G12, which has been reported to protect macaques against CXCR4-using SHIV challenge at relatively low serum neutralizing titers. Here, we investigated the ability of 2G12 administered intravenously (i.v.) to protect against vaginal challenge of rhesus macaques with the CCR5-using SHIVSF162P3. The results show that, at 2G12 serum neutralizing titers of the order of 1∶1 (IC90), 3/5 antibody-treated animals were protected with sterilizing immunity, i.e. no detectable virus replication following challenge; one animal showed a delayed and lowered primary viremia and the other animal showed a course of infection similar to 4 control animals. This result contrasts strongly with the typically high titers observed for protection by other neutralizing antibodies, including the bNAb b12. We compared b12 and 2G12 for characteristics that might explain the differences in protective ability relative to neutralizing activity. We found no evidence to suggest that 2G12 transudation to the vaginal surface was significantly superior to b12. We also observed that the ability of 2G12 to inhibit virus replication in target cells through antibody-mediated effector cell activity in vitro was equivalent or inferior to b12. The results raise the possibility that some epitopes on HIV may be better vaccine targets than others and support targeting the glycan shield of the envelope.Author SummaryAn effective HIV vaccine should elicit broadly neutralizing antibodies, i.e. antibodies that neutralize a wide spectrum of different HIVs in vitro. A number of human monoclonal antibodies have been isolated with broad neutralization and shown to protect macaques against vaginal HIV challenge. Protection is generally correlated with neutralization and requires relatively high antibody concentrations that may be difficult to achieve by vaccination. Here, we show that one monoclonal antibody (2G12) is unusually potent in protection relative to its neutralizing ability as hinted at by earlier data. Further studies eliminate an unusual ability of 2G12 to be transported to the vagina (site of infection) as a possible explanation for our observations. Although the precise mechanism is unclear, the studies have important implications for HIV vaccine design in general by suggesting that some vaccine targets on HIV may be better than others and, specifically, by suggesting that the sugar coat of HIV may be a particularly rewarding target if appropriate immunogens can be designed.

Published
2009

15. Localized populations of CD8 MHC class I tetramer SIV-specific T cells in lymphoid follicles and genital epithelium.

Author

Hong, Jung Joo, Reynolds, Matthew R, Mattila, Teresa L, Hage, Aaron, Watkins, David I, Miller, Christopher J, and Skinner, Pamela J

Subjects
Cervix Uteri, Vagina, Epithelium, Lymph Nodes, Spleen, CD8-Positive T-Lymphocytes, T-Lymphocytes, Cytotoxic, Animals, Rabbits, Macaca mulatta, Mice, Staining and Labeling, Major Histocompatibility Complex, Female, Simian immunodeficiency virus, Simian Immunodeficiency Virus, T-Lymphocytes, Cytotoxic, General Science & Technology
Abstract

CD8 T cells play an important role in controlling viral infections. We investigated the in situ localization of simian immunodeficiency virus (SIV)-specific T cells in lymph and genital tissues from SIV-infected macaques using MHC-class I tetramers. The majority of tetramer-binding cells localized in T cell zones and were CD8(+). Curiously, small subpopulations of tetramer-binding cells that had little to no surface CD8 were detected in situ both early and late post-infection, and in both vaginally and rectally inoculated macaques. These tetramer(+)CD8(low/-) cells were more often localized in apparent B cell follicles relative to T cell zones and more often found near or within the genital epithelium than the submucosa. Cells analyzed by flow cytometry showed similar populations of cells. Further immunohistological characterization revealed small populations of tetramer(+)CD20(-) cells inside B cell follicles and that tetramer(+) cells did not stain with gammadelta-TCR nor CD4 antibodies. Negative control tetramer staining indicated that tetramer(+)CD8(low/-) cells were not likely NK cells non-specifically binding to MHC tetramers. These findings have important implications for SIV-specific and other antigen-specific T cell function in these specific tissue locations, and suggest a model in which antigen-specific CD8+ T cells down modulate CD8 upon entering B cell follicles or the epithelial layer of tissues, or alternatively a model in which only antigen-specific CD8 T cells that down-modulate CD8 can enter B cell follicles or the epithelium.

Published
2009

16. Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys

Author

Magnani, Diogo M., Ricciardi, Michael J., Bailey, Varian K., Gutman, Martin J., Pedreño-Lopez, Núria, Silveira, Cassia G.T., Maxwell, Helen S., Domingues, Aline, Gonzalez-Nieto, Lucas, Su, Qin, Newman, Ruchi M., Pack, Melissa, Martins, Mauricio A., Martinez-Navio, José M., Fuchs, Sebastian P., Rakasz, Eva G., Allen, Todd M., Whitehead, Stephen S., Burton, Dennis R., Gao, Guangping, Desrosiers, Ronald C., Kallas, Esper G., and Watkins, David I.

Published
2017
Full Text
View/download PDF

17. Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network

Author

Aliota, Matthew T., Bassit, Leda, Bradrick, Shelton S., Cox, Bryan, Garcia-Blanco, Mariano A., Gavegnano, Christina, Friedrich, Thomas C., Golos, Thaddeus G., Griffin, Diane E., Haddow, Andrew D., Kallas, Esper G., Kitron, Uriel, Lecuit, Marc, Magnani, Diogo M., Marrs, Caroline, Mercer, Natalia, McSweegan, Edward, Ng, Lisa F.P., O'Connor, David H., Osorio, Jorge E., Ribeiro, Guilherme S., Ricciardi, Michael, Rossi, Shannan L., Saade, George, Schinazi, Raymond F., Schott-Lerner, Geraldine O., Shan, Chao, Shi, Pei-Yong, Watkins, David I., Vasilakis, Nikos, and Weaver, Scott C.

Published
2017
Full Text
View/download PDF

18. Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection

Author

Ricciardi, Michael J., primary, Rust, Lauren N., additional, Pedreño-Lopez, Nuria, additional, Yusova, Sofiya, additional, Biswas, Sreya, additional, Webb, Gabriela M., additional, Gonzalez-Nieto, Lucas, additional, Voigt, Thomas B., additional, Louw, Johan J., additional, Laurino, Fernanda D., additional, DiBello, John R., additional, Raué, Hans-Peter, additional, Barber-Axthelm, Aaron M., additional, Chun, Kimberly, additional, Uttke, Samantha, additional, Raphael, Lidiane M. S., additional, Yrizarry-Medina, Aaron, additional, Rosen, Brandon C., additional, Agnor, Rebecca, additional, Gao, Lina, additional, Labriola, Caralyn, additional, Axthelm, Michael, additional, Smedley, Jeremy, additional, Julander, Justin G., additional, Bonaldo, Myrna C., additional, Walker, Laura M., additional, Messaoudi, Ilhem, additional, Slifka, Mark K., additional, Burton, Dennis R., additional, Kallas, Esper G., additional, Sacha, Jonah B., additional, Watkins, David I., additional, and Burwitz, Benjamin J., additional

Published
2023
Full Text
View/download PDF

21. Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques

Author

Magnani, Diogo M., Rogers, Thomas F., Beutler, Nathan, Ricciardi, Michael J., Bailey, Varian K., Gonzalez-Nieto, Lucas, Briney, Bryan, Sok, Devin, Le, Khoa, Strubel, Alexander, Gutman, Martin J., Pedreño-Lopez, Núria, Grubaugh, Nathan D., Silveira, Cassia G. T., Maxwell, Helen S., Domingues, Aline, Martins, Mauricio A., Lee, David E., Okwuazi, Erica E., Jean, Sherrie, Strobert, Elizabeth A., Chahroudi, Ann, Silvestri, Guido, Vanderford, Thomas H., Kallas, Esper G., Desrosiers, Ronald C., Bonaldo, Myrna C., Whitehead, Stephen S., Burton, Dennis R., and Watkins, David I.

Published
2017
Full Text
View/download PDF

25. Plasmablast Expansion Following the Tetravalent, Live-Attenuated Dengue Vaccine Butantan-DV in DENV-Naïve and DENV-Exposed Individuals in a Brazilian Cohort

Author

Silveira, Cássia G. T., primary, Magnani, Diogo M., additional, Costa, Priscilla R., additional, Avelino-Silva, Vivian I., additional, Ricciardi, Michael J., additional, Timenetsky, Maria do Carmo S. T., additional, Goulart, Raphaella, additional, Correia, Carolina A., additional, Marmorato, Mariana P., additional, Ferrari, Lilian, additional, Nakagawa, Zelinda B., additional, Tomiyama, Claudia, additional, Tomiyama, Helena, additional, Kalil, Jorge, additional, Palacios, Ricardo, additional, Precioso, Alexander R., additional, Watkins, David I., additional, and Kallás, Esper G., additional

Published
2022
Full Text
View/download PDF

26. Therapeutic neutralizing monoclonal antibody administration protects against lethal viscerotropic Yellow Fever infection

Author

Ricciardi, Michael J., primary, Rust, Lauren N., additional, Pedreño-Lopez, Nuria, additional, Yusova, Sofiya, additional, Biswas, Sreya, additional, Webb, Gabriela M., additional, Fischer, Miranda, additional, Gonsales-Nieto, Lucas, additional, Voigt, Thomas B., additional, Louw, Johan J., additional, Laurino, Fernanda D., additional, DiBello, John R., additional, Raué, Hans-Peter, additional, Raphael, Lidiane M.S., additional, Yrizarry-Medina, Aaron, additional, Rosen, Brandon C., additional, Agnor, Rebecca, additional, Gao, Lina, additional, Labriola, Caralyn, additional, Axthelm, Michael, additional, Smedley, Jeremy, additional, Julander, Justin G., additional, Bonaldo, Myrna C., additional, Walker, Laura M., additional, Slifka, Mark K., additional, Messaoudi, Ilhem, additional, Burton, Dennis R., additional, Kallas, Esper G., additional, Sacha, Jonah B., additional, Watkins, David I., additional, and Burwitz, Benjamin J., additional

Published
2022
Full Text
View/download PDF

29. HIV Vaccine Research: The Way Forward

Author

Fauci, Anthony S., Johnston, Margaret I., Dieffenbach, Carl W., Burton, Dennis R., Hammer, Scott M., Hoxie, James A., Martin, Malcolm, Overbaugh, Julie, Watkins, David I., Mahmoud, Adel, and Greene, Warner C.

Published
2008
Full Text
View/download PDF

35. Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus

Author

Zhao, Fangzhu, primary, Berndsen, Zachary T., additional, Pedreño-Lopez, Nuria, additional, Burns, Alison, additional, Allen, Joel D., additional, Barman, Shawn, additional, Lee, Wen-Hsin, additional, Chakraborty, Srirupa, additional, Gnanakaran, Sandrasegaram, additional, Sewall, Leigh M., additional, Ozorowski, Gabriel, additional, Limbo, Oliver, additional, Song, Ge, additional, Yong, Peter, additional, Callaghan, Sean, additional, Weisgrau, Kim L., additional, Lifson, Jeffrey D., additional, Nedellec, Rebecca, additional, Voigt, Thomas B, additional, Laurino, Fernanda, additional, Louw, Johan, additional, Rosen, Brandon C., additional, Ricciardi, Michael, additional, Crispin, Max, additional, Desrosiers, Ronald C., additional, Rakasz, Eva G., additional, Watkins, David I., additional, Andrabi, Raiees, additional, Ward, Andrew B., additional, Burton, Dennis R., additional, and Sok, Devin, additional

Published
2021
Full Text
View/download PDF

40. Genotype-specific Features Reduce the Susceptibility of South American Yellow Fever Virus Strains to Vaccine-Induced Antibodies

Author

Haslwanter, Denise, primary, Lasso, Gorka, additional, Wec, Anna Z., additional, Furtado, Nathália Dias, additional, Raphael, Lidiane Menezes Souza, additional, Sun, Yan, additional, Stransky, Stephanie, additional, Pedreño-Lopez, Núria, additional, Tse, Alexandra, additional, Correia, Carolina Argondizo, additional, Bornholdt, Zachary A., additional, Sakharkar, Mrunal, additional, Avelino-Silva, Vivian I., additional, Moyer, Crystal L., additional, Watkins, David I., additional, Kallas, Esper G., additional, Sidoli, Simone, additional, Walker, Laura M., additional, Bonaldo, Myrna C., additional, and Chandran, Kartik, additional

Published
2021
Full Text
View/download PDF

44. The role of MHC class I allele Mamu-A*07 during SIVmac239 infection

Author

Reed, Jason S., Sidney, John, Piaskowski, Shari M., Glidden, Chrystal E., León, Enrique J., Burwitz, Benjamin J., Kolar, Holly L., Eernisse, Christopher M., Furlott, Jessica R., Maness, Nicholas J., Walsh, Andrew D., Rudersdorf, Richard A., Bardet, Wilfried, McMurtrey, Curtis P., O’Connor, David H., Hildebrand, William H., Sette, Alessandro, Watkins, David I., and Wilson, Nancy A.

Published
2011
Full Text
View/download PDF

48. The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques—implications for recombinant vaccine design

Author

Mudd, Philip A., Piaskowski, Shari M., Neves, Patricia C. Costa, Rudersdorf, Richard, Kolar, Holly L., Eernisse, Christopher M., Weisgrau, Kim L., de Santana, Marlon G. Veloso, Wilson, Nancy A., Bonaldo, Myrna C., Galler, Ricardo, Rakasz, Eva G., and Watkins, David I.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results